Skip to main content
Premium Trial:

Request an Annual Quote

Biosearch Licenses Access to New H1N1 Signatures from CDC

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biosearch Technologies today said that it has licensed from the US Centers for Disease Control and Prevention the new "pdm" H1N1 signatures.

According to Biosearch, the new pdm panel has been optimized for enhanced sensitivity and specificity for H1N1 specimens. The new signatures qualitatively detect currently circulating Novel 2009 H1N1 and offer improved performance over the probe and primer sequences previously published on the World Health Organization’s website, the Novato, Calif.-based firm added.

"As licensors of CDC influenza signatures and as the inventors of BHQ (Black Hole Quencher) technology, Biosearch will provide access to 5’-Nuclease BHQ probes that meet CDC design and manufacturing specifications for PDM Novel 2009 H1N1 testing labs around the world," Marc Beal, director of corporate development at Biosearch, said in a statement.

Terms of the license were not disclosed.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.